Robert Ainscow Sells 8,438 Shares of ASP Isotopes (NASDAQ:ASPI) Stock

Key Points

• Robert Ainscow, COO of ASP Isotopes, sold 8,438 shares of the company's stock for approximately $71,976, reducing his ownership by 0.59% but still retaining over 1.4 million shares.
• ASP Isotopes reported disappointing quarterly earnings, with an EPS of ($1.03) and revenues of $1.20 million, falling short of analysts' expectations.
• Canaccord Genuity Group upgraded ASP Isotopes to a "buy" rating, increasing its price target from $8.50 to $11.00 amid positive growth forecasts.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) COO Robert Ainscow sold 8,438 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $8.53, for a total transaction of $71,976.14. Following the completion of the transaction, the chief operating officer owned 1,411,554 shares of the company's stock, valued at $12,040,555.62. This trade represents a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

ASP Isotopes Price Performance

ASP Isotopes stock traded down $0.16 during mid-day trading on Monday, hitting $8.61. 1,550,161 shares of the company traded hands, compared to its average volume of 3,197,048. The stock has a market cap of $791.00 million, a price-to-earnings ratio of -14.14 and a beta of 3.35. The company has a debt-to-equity ratio of 3.53, a quick ratio of 14.56 and a current ratio of 14.72. ASP Isotopes Inc. has a one year low of $2.55 and a one year high of $11.68. The stock has a fifty day moving average price of $9.15 and a 200-day moving average price of $7.18.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.92). ASP Isotopes had a negative net margin of 2,181.62% and a negative return on equity of 239.22%. The firm had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.60 million. On average, equities analysts predict that ASP Isotopes Inc. will post -0.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group boosted their price objective on shares of ASP Isotopes from $8.50 to $11.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $7.75.

Institutional Investors Weigh In On ASP Isotopes

A number of institutional investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. grew its holdings in ASP Isotopes by 41.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company's stock valued at $40,000 after buying an additional 1,600 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of ASP Isotopes by 9.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,840 shares of the company's stock valued at $153,000 after acquiring an additional 1,878 shares during the last quarter. Bank of Montreal Can boosted its position in shares of ASP Isotopes by 8.0% during the 2nd quarter. Bank of Montreal Can now owns 27,000 shares of the company's stock valued at $199,000 after acquiring an additional 2,000 shares during the last quarter. Rathbones Group PLC boosted its position in shares of ASP Isotopes by 1.1% during the 2nd quarter. Rathbones Group PLC now owns 208,149 shares of the company's stock valued at $1,532,000 after acquiring an additional 2,220 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company's stock valued at $41,000 after acquiring an additional 2,548 shares during the last quarter. 16.80% of the stock is owned by hedge funds and other institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.